ANTIEPILEPTIC DRUGS TOPIRAMATE (Topamax)
{"Image DocumentName": "ANTIEPILEPTIC DRUGS TOPIRAMATE (Topamax)", "Image ImageDescription": "Prolong the Na inactivated channels. Enhance GABA current. Blocks the AMPA (glutamate) receptor. Carbonic anhydrase inhibitor. Used in the treatment of Partial seizures, Generalized tonic-clonic seizures, Lennox-Gastaut syndrome and migraine prophylaxis. Weight loss and renal stones. Topiramate (brand name Topamax) is an anticonvulsant drug. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder, although it is not FDA approved for this purpose and such use is somewhat controversial. This drug has been investigated for use in treatment of obesity, especially to aid in the reduction of binge eating, and also as a possible treatment for alcoholism. However, these uses are not actively promoted by the manufacturer, and like its use for bipolar disorder, are off-label uses. The drug is also used in clinical trials to treat Post Traumatic Stress Disorder[9]. A pilot study suggests that Topiramate is possibly effective against infantile spasm. In May 2006 the U.S. National Institutes of Health web site clinical trials. gov listed several studies sponsored by Ortho-McNeil which propose to examine the use of topiramate on migraine, cluster, and severe headaches within various demographics. Other off-label and investigational uses of Topiramate include: treatment of bulimia nervosa, obsessive-compulsive disorder, smoking cessation, treatment of neuropathic pain. Topiramate adverse effects : Cognitive impairment, confusion, dizziness, ataxia, headache. Agitation, emotional liability. Nausea, anorexia, weight loss. Acute angle-closure glaucoma The Food and Drug Administration (FDA) has issued a notification alerting physicians who prescribe topiramate, and their patients, to the risk of vision loss (blindness). Acute myopia and secondary angle closure glaucoma, in a small subset of patients who take topiramate regularly, may cause transient (reversible), or permanent, loss of vision. The symptoms, which typically begin in the first month of use, include blurred vision and eye pain.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}